Jaguar Health Regains Nasdaq Bid-Price Compliance, Delisting Threat Lifted
JAGX sits 17% above its 52-week low of $2.53.
Summary
Jaguar Health has successfully regained compliance with Nasdaq's minimum $1.00 bid price requirement, effectively removing the immediate delisting threat. This positive development follows a delisting notice issued on March 6, 2026, and a 1:35 reverse stock split on April 30, 2026, which significantly boosted the share price. While the company avoids delisting, it will remain under a mandatory one-year monitoring period by the Nasdaq Hearings Panel until May 26, 2027, requiring consistent adherence to the bid price rule. Maintaining this compliance is crucial for the micro-cap company's access to capital markets.
At the time of this announcement, JAGX was trading at $2.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $2.53 to $171.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.